A report on orphan drugs has shown that the median cost per patient is 5.5 times higher for orphan drugs compared to other medicines.
The average US cost per patient per year for an orphan drug was $140,443 in 2016, compared with $27,756 for a non-orphan, according to the EvaluatePharma Orphan Drug 2017 Report.
It also predicts continued growth at a compound annual growth rate from 2017 to 2022 of 11.1% for orphan drugs, approximately double overall prescription market growth.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze